In HG-SOC, inhibition of ID4 in vivo suppresses the growth of established tumors and significantly improves survival, suggesting that targeting ID4 expression is a viable therapeutic strategy in cancers that over-express ID4 [16]. Here, ID4 is linked to cancer.